{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T09:51:34Z","timestamp":1776851494527,"version":"3.51.2"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40262-025-01540-1","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T08:27:10Z","timestamp":1751444830000},"page":"1395-1411","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Population Pharmacokinetic and Pharmacodynamic Modelling and Simulation for Nedosiran Clinical Development and Dose Guidance in Pediatric Patients with Primary Hyperoxaluria Type 1"],"prefix":"10.1007","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-3555-8011","authenticated-orcid":false,"given":"Steven","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2429-0984","authenticated-orcid":false,"given":"Pablo","family":"Gamallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verity","family":"Rawson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"issue":"7","key":"1540_CR1","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1056\/NEJMra1301564","volume":"369","author":"P Cochat","year":"2013","unstructured":"Cochat P, Rumsby G. Primary hyperoxaluria. N Engl J Med. 2013;369(7):649\u201358. https:\/\/doi.org\/10.1056\/NEJMra1301564.","journal-title":"N Engl J Med"},{"issue":"8","key":"1540_CR2","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nrneph.2012.113","volume":"8","author":"B Hoppe","year":"2012","unstructured":"Hoppe B. An update on primary hyperoxaluria. Nat Rev Nephrol. 2012;8(8):467\u201375. https:\/\/doi.org\/10.1038\/nrneph.2012.113.","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"1540_CR3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00240-019-01166-6","volume":"48","author":"DJ Sas","year":"2020","unstructured":"Sas DJ, Harris PC, Milliner DS. Correction to: recent advances in the identification and management of inherited hyperoxalurias. Urolithiasis. 2020;48(1):93. https:\/\/doi.org\/10.1007\/s00240-019-01166-6.","journal-title":"Urolithiasis"},{"issue":"22","key":"1540_CR4","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1056\/NEJMc1311606","volume":"369","author":"G Rumsby","year":"2013","unstructured":"Rumsby G, Cochat P. Primary hyperoxaluria (in Eng). N Engl J Med. 2013;369(22):2163. https:\/\/doi.org\/10.1056\/NEJMc1311606.","journal-title":"N Engl J Med"},{"issue":"10","key":"1540_CR5","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1681\/ASN.2014070698","volume":"26","author":"K Hopp","year":"2015","unstructured":"Hopp K, et al. Phenotype-genotype correlations and estimated carrier frequencies of primary hyperoxaluria (in Eng). J Am Soc Nephrol. 2015;26(10):2559\u201370. https:\/\/doi.org\/10.1681\/ASN.2014070698.","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"1540_CR6","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1021\/acsptsci.2c00110","volume":"5","author":"A Liu","year":"2022","unstructured":"Liu A, et al. Nedosiran, a candidate siRNA drug for the treatment of primary hyperoxaluria: design, development, and clinical studies (in Eng). ACS Pharmacol Transl Sci. 2022;5(11):1007\u201316. https:\/\/doi.org\/10.1021\/acsptsci.2c00110.","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"3","key":"1540_CR7","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41585-021-00543-4","volume":"19","author":"K Shee","year":"2022","unstructured":"Shee K, Stoller ML. Perspectives in primary hyperoxaluria\u2014historical, current and future clinical interventions (in Eng). Nat Rev Urol. 2022;19(3):137\u201346. https:\/\/doi.org\/10.1038\/s41585-021-00543-4.","journal-title":"Nat Rev Urol"},{"issue":"3","key":"1540_CR8","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/s41581-022-00661-1","volume":"19","author":"JW Groothoff","year":"2023","unstructured":"Groothoff JW, et al. Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope (in Eng). Nat Rev Nephrol. 2023;19(3):194\u2013211. https:\/\/doi.org\/10.1038\/s41581-022-00661-1.","journal-title":"Nat Rev Nephrol"},{"key":"1540_CR9","doi-asserted-by":"publisher","DOI":"10.4061\/2011\/864580","volume":"2011","author":"J Harambat","year":"2011","unstructured":"Harambat J, Fargue S, Bacchetta J, Acquaviva C, Cochat P. Primary hyperoxaluria. Int J Nephrol. 2011;2011: 864580. https:\/\/doi.org\/10.4061\/2011\/864580.","journal-title":"Int J Nephrol"},{"issue":"10","key":"1540_CR10","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00467-012-2329-z","volume":"28","author":"VO Edvardsson","year":"2013","unstructured":"Edvardsson VO, et al. Hereditary causes of kidney stones and chronic kidney disease (in Eng). Pediatr Nephrol. 2013;28(10):1923\u201342. https:\/\/doi.org\/10.1007\/s00467-012-2329-z.","journal-title":"Pediatr Nephrol"},{"issue":"12","key":"1540_CR11","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/ki.2009.32","volume":"75","author":"B Hoppe","year":"2009","unstructured":"Hoppe B, Beck BB, Milliner DS. The primary hyperoxalurias. Kidney Int. 2009;75(12):1264\u201371. https:\/\/doi.org\/10.1038\/ki.2009.32.","journal-title":"Kidney Int"},{"issue":"10","key":"1540_CR12","doi-asserted-by":"publisher","first-page":"3855","DOI":"10.1093\/ndt\/gfs320","volume":"27","author":"SM van der Hoeven","year":"2012","unstructured":"van der Hoeven SM, van Woerden CS, Groothoff JW. Primary hyperoxaluria type 1, a too often missed diagnosis and potentially treatable cause of end-stage renal disease in adults: results of the Dutch cohort. Nephrol Dial Transplant. 2012;27(10):3855\u201362. https:\/\/doi.org\/10.1093\/ndt\/gfs320.","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"1540_CR13","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/ki.2014.222","volume":"86","author":"G Mandrile","year":"2014","unstructured":"Mandrile G, et al. Data from a large European study indicate that the outcome of primary hyperoxaluria type 1 correlates with the AGXT mutation type. Kidney Int. 2014;86(6):1197\u2013204. https:\/\/doi.org\/10.1038\/ki.2014.222.","journal-title":"Kidney Int"},{"issue":"20","key":"1540_CR14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2107661","volume":"385","author":"SF Garrelfs","year":"2021","unstructured":"Garrelfs SF, Gansner JM, Lieske JC. Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1. Reply (in Eng). N Engl J Med. 2021;385(20): e69. https:\/\/doi.org\/10.1056\/NEJMc2107661.","journal-title":"N Engl J Med"},{"issue":"4","key":"1540_CR15","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.ekir.2021.01.029","volume":"6","author":"G Ariceta","year":"2021","unstructured":"Ariceta G, Barrios K, Brown BD, Hoppe B, Rosskamp R, Langman CB. Hepatic lactate dehydrogenase a: an RNA interference target for the treatment of all known types of primary hyperoxaluria (in Eng). Kidney Int Rep. 2021;6(4):1088\u201398. https:\/\/doi.org\/10.1016\/j.ekir.2021.01.029.","journal-title":"Kidney Int Rep"},{"issue":"2","key":"1540_CR16","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s40265-024-01996-8","volume":"84","author":"YY Syed","year":"2024","unstructured":"Syed YY. Correction to: nedosiran: first approval. Drugs. 2024;84(2):255. https:\/\/doi.org\/10.1007\/s40265-024-01996-8.","journal-title":"Drugs"},{"key":"1540_CR17","unstructured":"FDA. RIVFLOZA (nedosiran) injection, for subcutaneous use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/215842s000lbl.pdf. Accessed."},{"issue":"3","key":"1540_CR18","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.kint.2021.08.015","volume":"101","author":"B Hoppe","year":"2022","unstructured":"Hoppe B, et al. Safety, pharmacodynamics, and exposure-response modeling results from a first-in-human phase 1 study of nedosiran (PHYOX1) in primary hyperoxaluria. Kidney Int. 2022;101(3):626\u201334. https:\/\/doi.org\/10.1016\/j.kint.2021.08.015.","journal-title":"Kidney Int"},{"issue":"8","key":"1540_CR19","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1016\/j.ymthe.2018.05.016","volume":"26","author":"C Lai","year":"2018","unstructured":"Lai C, et al. Specific inhibition of hepatic lactate dehydrogenase reduces oxalate production in mouse models of primary hyperoxaluria (in Eng). Mol Ther. 2018;26(8):1983\u201395. https:\/\/doi.org\/10.1016\/j.ymthe.2018.05.016.","journal-title":"Mol Ther"},{"issue":"1","key":"1540_CR20","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","volume":"5","author":"B Hu","year":"2020","unstructured":"Hu B, et al. Therapeutic siRNA: state of the art (in eng). Signal Transduct Target Ther. 2020;5(1):101. https:\/\/doi.org\/10.1038\/s41392-020-0207-x.","journal-title":"Signal Transduct Target Ther"},{"key":"1540_CR21","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.omtn.2022.06.005","volume":"29","author":"BMDC Godinho","year":"2022","unstructured":"Godinho BMDC, et al. PK-modifying anchors significantly alter clearance kinetics, tissue distribution, and efficacy of therapeutics siRNAs (in eng). Mol Ther Nucleic Acids. 2022;29:116\u201332. https:\/\/doi.org\/10.1016\/j.omtn.2022.06.005.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1 Pt 1","key":"1540_CR22","doi-asserted-by":"publisher","first-page":"C289","DOI":"10.1152\/ajpcell.1997.272.1.C289","volume":"272","author":"RE Poore","year":"1997","unstructured":"Poore RE, Hurst CH, Assimos DG, Holmes RP. Pathways of hepatic oxalate synthesis and their regulation (in eng). Am J Physiol. 1997;272(1 Pt 1):C289\u201394. https:\/\/doi.org\/10.1152\/ajpcell.1997.272.1.C289.","journal-title":"Am J Physiol"},{"issue":"2","key":"1540_CR23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.bbapap.2005.08.004","volume":"1753","author":"K Mdluli","year":"2005","unstructured":"Mdluli K, Booth MP, Brady RL, Rumsby G. A preliminary account of the properties of recombinant human glyoxylate reductase (GRHPR), LDHA and LDHB with glyoxylate, and their potential roles in its metabolism (in eng). Biochim Biophys Acta. 2005;1753(2):209\u201316. https:\/\/doi.org\/10.1016\/j.bbapap.2005.08.004.","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"1540_CR24","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/0006-2944(72)90018-x","volume":"6","author":"LH Smith","year":"1972","unstructured":"Smith LH, Bauer RL, Craig JC, Chan RP, Williams HE. Inhibition of oxalate synthesis: in vitro studies using analogues of oxalate and glycolate (in eng). Biochem Med. 1972;6(4):317\u201332. https:\/\/doi.org\/10.1016\/0006-2944(72)90018-x.","journal-title":"Biochem Med"},{"issue":"3969","key":"1540_CR25","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1126\/science.171.3969.390","volume":"171","author":"HE Williams","year":"1971","unstructured":"Williams HE, Smith LH. Hyperoxaluria in L-glyceric aciduria: possible pathogenic mechanism (in eng). Science. 1971;171(3969):390\u20131. https:\/\/doi.org\/10.1126\/science.171.3969.390.","journal-title":"Science"},{"key":"1540_CR26","doi-asserted-by":"crossref","unstructured":"Holmes RP, Assimos DG. Glyoxylate synthesis, and its modulation and influence on oxalate synthesis (in Eng). J Urol. 1998;160(5):1617\u201324 [Online]. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9783918.","DOI":"10.1016\/S0022-5347(01)62363-2"},{"issue":"1","key":"1540_CR27","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.kint.2022.07.025","volume":"103","author":"MA Baum","year":"2023","unstructured":"Baum MA, et al. PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2 (in Eng). Kidney Int. 2023;103(1):207\u201317. https:\/\/doi.org\/10.1016\/j.kint.2022.07.025.","journal-title":"Kidney Int"},{"issue":"5","key":"1540_CR28","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/j.ekir.2024.02.1439","volume":"9","author":"J Groothoff","year":"2024","unstructured":"Groothoff J, et al. Nedosiran safety and efficacy in PH1: interim analysis of PHYOX3. Kidney Int Rep. 2024;9(5):1387\u201396. https:\/\/doi.org\/10.1016\/j.ekir.2024.02.1439.","journal-title":"Kidney Int Rep"},{"key":"1540_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.16194","author":"S Zhang","year":"2024","unstructured":"Zhang S, et al. Nedosiran population pharmacokinetic and pharmacodynamic modelling and simulation to guide clinical development and dose selection in patients with primary hyperoxaluria type 1. Br J Clin Pharmacol. 2024. https:\/\/doi.org\/10.1111\/bcp.16194.","journal-title":"Br J Clin Pharmacol"},{"key":"1540_CR30","unstructured":"ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice E6(R2), Current Step 5 version, 1 December. [Online]. Available: ICH: E 6 (R2): Guideline for good clinical practice\u2014Step 5 (europa.eu)"},{"key":"1540_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1320","author":"A Amrite","year":"2023","unstructured":"Amrite A, Fuentes E, Marbury TC, Zhang S. \"Safety, pharmacokinetics, and exposure-response modeling of nedosiran in participants with severe chronic kidney disease (in Eng). Clin Pharmacol Drug Dev. 2023. https:\/\/doi.org\/10.1002\/cpdd.1320.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"5","key":"1540_CR32","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1023\/a:1012299115260","volume":"28","author":"SL Beal","year":"2001","unstructured":"Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn. 2001;28(5):481\u2013504. https:\/\/doi.org\/10.1023\/a:1012299115260.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"3","key":"1540_CR33","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/j.1460-9592.2011.03536.x","volume":"21","author":"BJ Anderson","year":"2011","unstructured":"Anderson BJ, Holford NH. Tips and traps analyzing pediatric PK data. Paediatr Anaesth. 2011;21(3):222\u201337. https:\/\/doi.org\/10.1111\/j.1460-9592.2011.03536.x.","journal-title":"Paediatr Anaesth"},{"key":"1540_CR34","unstructured":"World Health Organization. The WHO child growth standards. Weight-for-age. https:\/\/www.who.int\/tools\/child-growth-standards\/standards\/weight-for-age."},{"key":"1540_CR35","unstructured":"National Center for Health Statistics (Center for Disease Control and Prevention). National Health and Nutrition Examination Survey. Continuous NHANES. https:\/\/wwwn.cdc.gov\/Nchs\/Nhanes\/."},{"issue":"1","key":"1540_CR36","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00467-008-0997-5","volume":"24","author":"MM Rhodin","year":"2009","unstructured":"Rhodin MM, et al. Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr Nephrol. 2009;24(1):67\u201376. https:\/\/doi.org\/10.1007\/s00467-008-0997-5.","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"1540_CR37","doi-asserted-by":"publisher","DOI":"10.1053\/AJKD034000e6","volume":"34","author":"V Matos","year":"1999","unstructured":"Matos V, Van Melle G, Werner D, Bardy D, Guignard JP. Urinary oxalate and urate to creatinine ratios in a healthy pediatric population (in Eng). Am J Kidney Dis. 1999;34(2): e1. https:\/\/doi.org\/10.1053\/AJKD034000e6.","journal-title":"Am J Kidney Dis"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01540-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01540-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01540-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T01:14:05Z","timestamp":1757466845000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01540-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1540"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01540-1","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"5 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported by Dicerna Pharmaceuticals, Inc., a Novo Nordisk Company (Lexington, MA, USA).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors are employees, and SZ and VR are shareholders of Novo Nordisk.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The institutional review board or ethics committee at each participating center approved the final study protocols.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from all adult participants and participating children\u2019s parents or legal guardians. The safety review committee convened at predefined decision points and the occurrence of any potential dose-limiting toxicities to ensure the acceptability of continued nedosiran administration within each study (and cohort) and of dose escalation to subsequent cohorts (where applicable).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data will be made available, on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Steven Zhang was responsible for the study conception and design. Model development and simulations were performed by Pablo Gamallo. Verity Rawson ensured medical accuracy. All authors participated in the interpretation of the study data, drafting of the manuscript, critical revision, and approval of the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}